Aldeyra Therapeutics, Inc. ALDX
0.63 USD -0.02 (-3.27%)
At closeNov 12, 2026, 4:00 PM EST
0.63 0.00 0.00%
After hours · Nov 12, 4:00 PM ET
0.60 Day range 0.65
0.527 52-week range 5.93
- YTD
- -87.84%
- 1 year
- -88.11%
News
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Silexion Therapeutics (NASDAQ:SLXN) shares moved upwards by 11.0% to $0.17 during Friday's after-market session. The company's market cap stands at $2.4 million. Lexaria Bioscience…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) shares moved upwards by 64.0% to $2.05 during Tuesday's after-market session. The market value of their outstanding shares is at $1.1 million. Neogen…- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers HeartBeam (NASDAQ:BEAT) stock moved upwards by 70.5% to $0.74 during Monday's regular session. The market value of their outstanding shares is at $24.4 million. PDS Biotechnology…
benzinga.com HC Wainwright & Co. Reiterates Neutral on Aldeyra Therapeutics, Maintains $2 Price Target HC Wainwright & Co. analyst Matthew Caufield reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Neutral and maintains $2 price target.
benzinga.com Aldeyra Fights Back Against FDA Rejection, Dispute Plan Triggers Rally Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) shares are trading higher on Tuesday as investors react to the company's intent to submit a formal dispute resolution request tied to its reproxalap program.
benzinga.com Aldeyra Fights Back Against FDA Rejection, Dispute Plan Triggers Rally Aldeyra Therapeutics stock surges as the company files an FDA dispute resolution for its dry eye drug reproxalap following a rejection.
seekingalpha.com Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye Disease Transcript Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye Disease Transcript
benzinga.com BTIG Reiterates Buy on Aldeyra Therapeutics, Maintains $9 Price Target BTIG analyst Thomas Shrader reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and maintains $9 price target.
marketbeat.com Aldeyra to Appeal FDA Rejection of Reproxalap for Dry Eye Disease Aldeyra Therapeutics NASDAQ: ALDX said it plans to submit a formal dispute resolution request, or FDRR, to the FDA's Office of New Drugs seeking review of the agency's latest complete response letter…
businesswire.com Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease CONCORD, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat…
businesswire.com Aldeyra Therapeutics to Host Regulatory Update Webcast CONCORD, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Gossamer Bio (NASDAQ:GOSS) shares moved upwards by 47.2% to $0.29 during Tuesday's pre-market session. The company's market cap stands at $97.4 million. Prelude Therapeutics (NASDAQ:PRLD)…
globenewswire.com Levicept Appoints Darlene Deptula-Hicks as CFO Highly Experienced US-Based Public Markets Leader Strengthens Team as Company Drives Late Stage Development of LEVI-04 for Osteoarthritis Highly Experienced US-Based Public Markets Leader Strengthens…
gurufocus.com Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immun
businesswire.com Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat…- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
marketbeat.com Aldeyra Therapeutics Eyes FDA Feedback as Dry Eye Drug Faces Make-or-Break Moment Aldeyra Therapeutics NASDAQ: ALDX Chief Executive Todd Brady said the company expects near-term feedback from the U.S. Food and Drug Administration on its dry eye disease candidate reproxalap,…
businesswire.com Aldeyra Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat…
newsfilecorp.com Bronstein, Gewirtz & Grossman LLC Urges Aldeyra Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm New York, New York--(Newsfile Corp. - May 29, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed…
gurufocus.com ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm [url="]The Schall Law Firm[/url], a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc.
gurufocus.com ALDX FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026 [url="]Faruqi and Faruqi, LLP[/url], a leading national securities law firm, is investigating potential claims against Aldeyra Therapeutics, Inc. (âAldeyraâ
businesswire.com ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm LOS ANGELES--(BUSINESS WIRE)---- $ALDX--ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm.
newsfilecorp.com ALDX FINAL DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 29 Deadline in Securities Class Action First Filed by the Firm - ALDX New York, New York--(Newsfile Corp. - May 29, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between…
businesswire.com ALDX FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026 NEW YORK--(BUSINESS WIRE)---- $ALDX #ALDX--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Aldeyra Therapeutics, Inc. (“Aldeyra” or the…
globenewswire.com ALDX UPCOMING DEADLINE : The Gross Law Firm Alerts Aldeyra Therapeutics, Inc. Stockholders of Securities Class Action - Contact the Firm NEW YORK, May 29, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX). Shareholders who purchased shares of ALDX…
newsfilecorp.com ALDX SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026 Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aldeyra To Contact Him Directly To Discuss Their Options If you purchased or…
prnewswire.com ALDX Deadline Tomorrow: ALDX Investors with Losses in Excess of $100K Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm NEW YORK, May 28, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between November 3, 2023…
globenewswire.com ALDEYRA DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 29 Deadline in Securities Class Action First Filed by the Firm - ALDX NEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between November 3,…- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com What's Going On With Aldeyra Therapeutics Stock On Thursday? Aldeyra stock plunges after FDA rejects its dry eye drug reproxalap, raising concerns over efficacy and future growth prospects.
benzinga.com This Trade Desk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday Analysts downgraded CF, ALDX, TTD, TME and DUOL. Check their ratings and price targets. Interested in TTD? See what analysts say.
benzinga.com HC Wainwright & Co. Downgrades Aldeyra Therapeutics to Neutral, Lowers Price Target to $2 HC Wainwright & Co. analyst Matthew Caufield downgrades Aldeyra Therapeutics (NASDAQ:ALDX) from Buy to Neutral and lowers the price target from $10 to $2.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com FDA Rejects Aldeyra's Dry Eye Drug For Third Time, Stock Crashes 68% Aldeyra stock crashes 68% after the FDA rejects its dry eye drug, reproxalap, for the third time. Get the full regulatory update here.
benzinga.com Crude Oil Gains Around 2%; Elbit Systems Shares Jump On Upbeat Earnings US stocks rose, with Dow Jones up 0.39% & NASDAQ up 0.59%. Energy shares jumped 1.7%, while industrials fell 0.1%. Elbit Systems shares up 10%.
benzinga.com Nasdaq Surges Over 100 Points; Academy Sports And Outdoors Posts Downbeat Earnings US stocks started higher this morning, with NASDAQ up over 100 points. Energy shares rose by 1.3%, while Aldeyra and Meiwu Tech saw sharp declines.
benzinga.com Aldeyra Therapeutics Receives CRL From FDA For NDA Of Reproxalap, Investigational Drug Candidate, For Treatment Of Dry Eye Disease Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced…- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
benzinga.com FDA Extends Review Timeline For Aldeyra's Dry Eye Disease Drug FDA extends Aldeyra's reproxalap PDUFA date to March 2026 after a major NDA amendment tied to new clinical study report data.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Why B. Riley Financial Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket - benzinga.com Aldeyra Therapeutics Expands RASP Platform To Include Programs In Central Nervous System Diseases Associated With Inflammation; Updates Manufacturing Information On Reproxalap Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced at a…
benzinga.com BTIG Reiterates Buy on Aldeyra Therapeutics, Maintains $9 Price Target BTIG analyst Thomas Shrader reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and maintains $9 price target.
benzinga.com 4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals 4 biotech stocks—ALDX, ALEC, BDTX, CHRS—show strong week-on-week momentum ranking gains and improving technical indicators.
benzinga.com 4 Biotech Stocks Seeing Explosive Momentum Gains The SPDR S&P Biotech ETF (ARCA:XBI) is up more than 40% over the past six months and is on the verge of breaking out. Here's a look at several momentum standouts in the biotech space that appear to…- benzinga.com Aldeyra Wins EMA Orphan Drug Status for ADX-2191 to Treat Rare Eye Cancer Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced that the European Medicines Agency (EMA) has granted Orphan Designation for ADX-2191 (methotrexate intravitreal injection, USP) for…
benzinga.com Aldeyra Therapeutics Says FDA Grants Fast Track Designation For ADX-2191 For Treatment Of Retinitis Pigmentosa Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for ADX-2191 (methotrexate intravitreal…
benzinga.com Aldeyra Resubmits Eye Drug for FDA Review After New Trial Clears Key Hurdle in Treating Dry Eye Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune‑mediated and metabolic diseases, today…
benzinga.com HC Wainwright & Co. Reiterates Buy on Aldeyra Therapeutics, Maintains $10 Price Target HC Wainwright & Co. analyst Matthew Caufield reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and maintains $10 price target.